NUWE

Nuwellis, Inc. (NUWE) - 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2026. Nuwellis, Inc. is a commercial-stage medical device company focused on the Aquadex SmartFlow system for ultrafiltration therapy in critical care settings. The company operates as a single segment and is headquartered in Eden Prairie, Minnesota. As of the reporting date, the company is classified as a non-accelerated filer and a smaller reporting company.

Key Financial Metrics

Note: The balance sheet reflects a significant warrant liability of $6.96 million as of June 30, 2026, which impacted the equity position.

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 14.1% year-over-year for the quarter and 20.5% for the six-month period, driven by a 209% increase in console sales and higher circuit usage.
• Margin Expansion: Gross margin improved significantly to 76.1% (Q2 2026) from 55.5% (Q2 2025), attributed to switching to contract manufacturing with KDI Precision Manufacturing.
• Expense Increases: Operating expenses rose due to increased headcount, sales compensation, and R&D investments. R&D expenses increased 39.6% for the quarter and 118.0% for the six-month period.
• Financing Activity: The company completed a public offering in June 2026 raising approximately $6.0 million in gross proceeds. This transaction resulted in the issuance of Series C and Series D warrants, which were classified as liabilities, creating a "Day 1" financing expense of approximately $6.08 million.
• Acquisition: The company acquired Rendiatech Ltd. in March 2026, accounted for as an asset acquisition, with deferred consideration liabilities recorded.

Outlook, Risks, and Unusual Items

• Going Concern: The filing includes a "substantial doubt" disclosure regarding the company's ability to continue as a going concern for at least 12 months due to an accumulated deficit of $325.7 million and continued operating losses. Management expects current capital to support operations into Q2 2027 but anticipates a need for additional financing.
• Nasdaq Compliance: As of June 30, 2026, reported stockholders' equity was below the Nasdaq minimum requirement due to warrant liability classification. However, subsequent events (warrant exercises and reclassifications) resulted in a pro forma equity of $4.39 million, which management believes restores compliance.
• Reverse Stock Split: A 1-for-35 reverse stock split was effectuated on June 25, 2026, triggering a reset of Series C warrant exercise prices to $2.72.
• Subsequent Events: In July 2026, the company raised an additional $3.4 million via a registered direct offering and received $3.3 million from the exercise of Series C warrants, significantly strengthening liquidity post-period.
• Internal Controls: Management concluded that disclosure controls and procedures were not effective as of June 30, 2026, citing two material weaknesses identified in the prior year's 10-K.

Investor Verification Checklist

• Warrant Liability Reclassification: Verify the status of the Series C and Series D warrant exercises and the resulting impact on the balance sheet to confirm the pro forma equity position meets Nasdaq listing standards.
• Cash Runway: Assess the sufficiency of the $3.92 million cash balance (plus subsequent proceeds) against the burn rate to confirm the ability to fund operations through Q2 2027 without further dilution.
• Revenue Concentration: Review customer concentration risks, noting that two customers represented 26% of sales in Q2 2026.
• Internal Control Remediation: Monitor progress on remediation plans for the identified material weaknesses in financial reporting controls.
• Acquisition Integration: Evaluate the integration progress and financial impact of the Rendiatech acquisition.